Technical Analysis for VCEL - Vericel Corporation

Grade Last Price % Change Price Change
C 44.19 -0.16% -0.07
VCEL closed down 0.16 percent on Monday, March 18, 2024, on 88 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Doji - Bullish? Reversal 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish -0.16%
Pocket Pivot Bullish Swing Setup -0.16%
Oversold Stochastic Weakness -0.16%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.05%
Gapped Down Weakness -0.05%
Oversold Stochastic Weakness -0.05%

   Recent Intraday Alerts

Alert Time
Down 1% about 14 hours ago
Fell Below Previous Day's Low about 15 hours ago
10 DMA Resistance about 15 hours ago
10 DMA Resistance 4 days ago
Non-ADX 1,2,3,4 Pullback Entry 4 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vericel Corporation Description

Vericel Corporation, a commercial-stage biopharmaceutical company, focuses on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets two autologous cell therapy products in the United States, including Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee; and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area. The company is also developing MACI, a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee; and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company, formerly known as Aastrom Biosciences, Inc., was founded in 1989 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Stem Cell Cell Therapy Heart Failure Knee Burns Cardiomyopathy Myopathy Cartilage Osteochondritis Dissecans Severe Diseases

Is VCEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 50.09
52 Week Low 28.02
Average Volume 463,594
200-Day Moving Average 36.99
50-Day Moving Average 43.68
20-Day Moving Average 45.91
10-Day Moving Average 44.58
Average True Range 1.50
RSI (14) 45.05
ADX 22.08
+DI 14.29
-DI 23.44
Chandelier Exit (Long, 3 ATRs) 45.59
Chandelier Exit (Short, 3 ATRs) 47.98
Upper Bollinger Bands 49.37
Lower Bollinger Band 42.45
Percent B (%b) 0.25
BandWidth 15.08
MACD Line -0.08
MACD Signal Line 0.33
MACD Histogram -0.417
Fundamentals Value
Market Cap 2.11 Billion
Num Shares 47.7 Million
EPS -0.21
Price-to-Earnings (P/E) Ratio -210.43
Price-to-Sales 11.98
Price-to-Book 10.92
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.92
Resistance 3 (R3) 45.87 45.25 45.63
Resistance 2 (R2) 45.25 44.81 45.27 45.53
Resistance 1 (R1) 44.72 44.54 44.41 44.77 45.44
Pivot Point 44.10 44.10 43.95 44.12 44.10
Support 1 (S1) 43.57 43.66 43.26 43.62 42.94
Support 2 (S2) 42.95 43.39 42.97 42.85
Support 3 (S3) 42.42 42.95 42.75
Support 4 (S4) 42.47